Prognostic value of HPV DNA in Urothelial Carcinoma of the Bladder: A Preliminary Report of 2-Year Follow-up Results Prognostic value of HPV in Urothelial Carcinoma of the Bladder
Vol. 19 No. 01 (2022),
18 March 2022
Purpose: The association between the human papillomavirus (HPV) and anogenital carcinomas is well established. However, despite its anatomic adjacency, the relationship between HPV and urothelial carcinoma of the bladder (UCB) is less clear. Recent meta-analysis and case-control studies demonstrated a significant relationship between the presence of HPV DNA and UCB. The aim of this clinical study was to compare the 2-year follow-up results of HPV-positive and HPV-negative UCB patients to evaluate the prognostic value of HPV DNA positivity in UCB.
Methods: The study included patients with stage pTa and pT1 UCB who underwent polymerase chain reaction (PCR) analysis of HPV DNA between January 1 and November 30, 2018. Based on their PCR results, 19 HPV-positive and 38 HPV-negative UCB patients who had regular follow-up in our clinic were evaluated in terms of tumor recurrence and disease progression over a 2-year follow-up period.
Results: There was no significant difference between the groups in terms of age, follow-up time, smoking, or tumor grade (P= .576, P= .368, P= .080, and P= .454). Tumor recurrence was observed at least once in 47.3% (n=9) of the 19 HPV-positive patients and 36.8% (n=14) of the 38 HPV-negative patients (P= .445). There was no difference in disease progression between the groups during follow-up.
Conclusion: In our sample of UCB patients, the presence of HPV DNA was associated with a trend toward higher recurrence rate during the 2-year follow-up, though the difference was not statistically significant. No difference in disease progression was observed based on HPV DNA positivity.
- Urothelial Carcinoma; Bladder; HPV; Prognosis; PCR
How to Cite
Tolstov Y, Hadaschik B, Pahernik S, Hohenfellner M, Duensing S. Human papillomaviruses in urological malignancies: a critical assessment. Urol Oncol. 2014;32:46.e19-27.
Cobos C, Figueroa JA, Mirandola L, et al. The Role of Human Papilloma Virus (HPV) Infection in Non-Anogenital Cancer and the Promise of Immunotherapy: A Review. Int Rev Immunol. 2014;33:383-401.
Sarier M, Ozel E, Duman I, Yuksel Y, Demirbas A. HPV type 45-positive condyloma acuminata of the bladder in a renal transplant recipient. Transpl Infect Dis. 2017;19:e12667.
de Villiers EM. Cross-roads in the classification of papillomaviruses. Virology. 2013;445:2-10.
Assmann G, Sotlar K. HPV-associated squamous cell carcinogenesis. Pathologe. 2011;32:391-398.
Urbute A, Rasmussen CL, Belmonte F, et al. Prognostic Significance of HPV DNA and p16 INK4a in Anal Cancer: A Systematic Review and Meta-Analysis . Cancer Epidemiol Biomarkers Prev. February 2020. doi:10.1158/1055-9965.epi-19-1259
Kao HL, Lai CR, Ho HL, Pan CC. Molecular typing for detection of high-risk human papillomavirus is a useful tool for distinguishing primary bladder carcinoma from secondary involvement of uterine cervical carcinoma in the urinary bladder. Histopathology. 2016;68:513-519.
Javanmard B, Barghi M reza, Amani D, Fallah-Karkan M, Mazloomfard MM. Human papilloma virus DNA in tumor tissue and urine in different stage of bladder cancer. Urol J. 2019;16:352-356.
Gutiérrez J, Jiménez A, de Dios Luna J, Soto MJ, Sorlózano A. Meta-analysis of studies analyzing the relationship between bladder cancer and infection by human papillomavirus. J Urol. 2006;176:2474-2481; discussion 2481.
Gould VE, Schmitt M, Vinokurova S, et al. Human papillomavirus and p16 expression in inverted papillomas of the urinary bladder. Cancer Lett. 2010;292:171-175.
Sarier M, Sepin N, Keles Y, et al. Is There any Association between Urothelial Carcinoma of the Bladder and Human Papillomavirus ? A Case-Control Study. Urol Int. 2019. doi:10.1159/000500467
Babjuk M, Burger M, Compérat EM, et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update. Eur Urol. 2019;76:639-657.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
Goyal S, Singh UR, Sharma S, Kaur N. Correlation of mitotic indices, AgNor count, Ki-67 and Bcl-2 with grade and stage in papillary urothelial bladder cancer. Urol J. 2014;11:1238-1247.
Chamie K, Litwin MS, Bassett JC, et al. Recurrence of high-risk bladder cancer: A population-based analysis. Cancer. 2013;119:3219-3227.
Sarier M, Ceyhan AM, Sepin N, et al. HPV infection in urology practice. Int Urol Nephrol. October 2019:1-8. doi:10.1007/s11255-019-02302-2
Kraus I, Molden T, Holm R, et al. Presence of E6 and E7 mRNA from human papillomavirus types 16, 18, 31, 33, and 45 in the majority of cervical carcinomas. J Clin Microbiol. 2006;44:1310-1317.
McLaughlin-Drubin ME, Crum CP, Münger K. Human papillomavirus E7 oncoprotein induces KDM6A and KDM6B histone demethylase expression and causes epigenetic reprogramming. Proc Natl Acad Sci U S A. 2011;108:2130-2135.
McLaughlin-Drubin ME, Park D, Munger K. Tumor suppressor p16INK4A is necessary for survival of cervical carcinoma cell lines. Proc Natl Acad Sci U S A. 2013;110:16175-16180.
Heidegger I, Borena W, Pichler R. The role of human papilloma virus in urological malignancies. Anticancer Res. 2015;35:2513-2519. http://www.ncbi.nlm.nih.gov/pubmed/25964524. Accessed November 30, 2018.
Visalli G, Facciolà A, Aleo FD, et al. Hpv and Urinary Bladder Carcinoma : a Review of the Literature. WCRJ. 2018;5(1):1-12.
Liu H, Li J, Zhou Y, Hu Q, Zeng Y, Mohammadreza MM. Human papillomavirus as a favorable prognostic factor in a subset of head and neck squamous cell carcinomas: A meta-analysis. J Med Virol. 2017;89:710-725.
Li P, Tan Y, Zhu LX, et al. Prognostic value of HPV DNA status in cervical cancer before treatment: A systematic review and meta-analysis. Oncotarget. 2017;8:66352-66359.
Kobayashi K, Hisamatsu K, Suzui N, Hara A, Tomita H, Miyazaki T. A Review of HPV-Related Head and Neck Cancer. J Clin Med. 2018;7:241.
Tenti P, Zappatore R, Romagnoli S, et al. p53 overexpression and human papillomavirus infection in transitional cell carcinoma of the urinary bladder: correlation with histological parameters. J Pathol. 1996;178:65-70.
Cai. Human papillomavirus and non-muscle invasive urothelial bladder cancer: Potential relationship from a pilot study. Oncol Rep. 2011;25(2). doi:10.3892/or.2010.1083
Zampronha R de AC, Freitas-Junior R, Murta EFC, et al. Human papillomavirus types 16 and 18 and the prognosis of patients with stage I cervical cancer. Clinics (Sao Paulo). 2013;68:809-814.
Mai S, Welzel G, Ottstadt M, et al. Prognostic Relevance of HPV Infection and p16 Overexpression in Squamous Cell Anal Cancer. Int J Radiat Oncol Biol Phys. 2015;93:819-827.
Jørgensen KR, Høyer S, Sørensen MM, Jensen JB. Human papillomavirus types 44, 52, 66 and 67 detected in a woman with squamous cell carcinoma of the urinary bladder. Scand J Urol. 2017;51:85-86.
Polesel J, Gheit T, Talamini R, et al. Urinary human polyomavirus and papillomavirus infection and bladder cancer risk. Br J Cancer. 2012;106:222-226.
- Abstract Viewed: 33 times